Organization

Takeshi Morimoto

4 clinical trials

Clinical trial
Optimal Duration of Anticoagulation Therapy for Low-risk Pulmonary Embolism Patients With Cancer
Status: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
GOREISAN for Heart Failure (GOREISAN-HF) Trial
Status: Recruiting, Estimated PCD: 2024-01-01